Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 166 results for fibrosis

  1. Cystic fibrosis: adherence to therapy (IND293)

    This indicator covers patient adherence to nebulised therapy in cystic fibrosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    30 September 2023

  2. Monitoring for cystic-fibrosis-related diabetes:- What is the most effective strategy to detect diabetes in people with cystic fibrosis?

    Monitoring for cystic-fibrosis-related diabetes:- What is the most effective strategy to detect diabetes in people with cystic...

    Research recommendation
    Published
    18 October 2018

  3. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  4. Cystic fibrosis: adherence to therapy (chronic pseudomonas acquisition) (IND294)

    This indicator covers normative adherence to nebulised therapy in cystic fibrosis for patients with chronic pseudomonas acquisition. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    30 September 2023

  5. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    27 November 2013
    View recommendations

    Sections for TA75

  6. Psychological assessment:- What is the most effective measure of psychological functioning to use as a test for thresholds of concern in people with cystic fibrosis?

    functioning to use as a test for thresholds of concern in people with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    18 October 2018

  7. Airway clearance techniques:- How effective are daily airway clearance techniques in maintaining lung function in infants and children with cystic fibrosis?

    techniques in maintaining lung function in infants and children with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    6 November 2018

  8. Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy at thresholds specified by the company, or the prognostic ability of MRE to predict clinical outcomes (see section 3.20 ).

    interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy...

    Research recommendation
    Published
    3 February 2023

  9. Non-invasive tests for diagnosing NASH:- Which non-invasive tests most accurately identify non-alcoholic steatohepatitis (NASH) in people with non-alcoholic fatty liver disease (NAFLD)?

    minority of people with NAFLD. It is thought to be the precursor of liver fibrosis, which is associated with morbidity and mortality. As...

    Research recommendation
    Published
    24 August 2016

  10. Soft-palate implants for simple snoring (IPG240)

    Evidence-based recommendations on soft-palate implants for simple snoring. This involves inserting implants into the soft palate of the mouth to make it stiffer and less likely to vibrate.

    Interventional procedures guidance
    Published
    28 November 2007
    View recommendations

    Sections for IPG240

  11. Living-donor lung transplantation for end-stage lung disease (IPG170)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    Interventional procedures guidance
    Published
    24 May 2006
    View recommendations

    Sections for IPG170

  12. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (IPG695)

    Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.

    Interventional procedures guidance
    Published
    26 May 2021
    View recommendations

    Sections for IPG695

  15. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation